{"id":338490,"date":"2026-11-04T11:17:34","date_gmt":"2026-11-04T05:47:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=338490"},"modified":"2026-11-04T11:17:34","modified_gmt":"2026-11-04T05:47:34","slug":"active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/","title":{"rendered":"3 Active Ingredients Maker, Artificial Leather Maker and Cardiovascular and CNS Medicines Company Stocks With a Strong Future Roadmap: Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals: ROE of 16.9% to 25.5% and FY22 to FY26 revenue CAGR of 10.9% to 21.1%. Prices as of 3 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three API maker, synthetic leather and drug stocks to watch are Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals. Their return on equity ranges from 16.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.9% to 21.1%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Neuland Laboratories has the fastest revenue growth at 21.1% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>API maker, synthetic leather and drug stocks give investors a way to track businesses that sit close to everyday demand in India. Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals cover an active ingredients maker, an artificial leather maker and a cardiovascular and CNS medicines company.<\/p>\n<p>This list covers three API maker, synthetic leather and drug stocks with complete current figures: Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#What_Are_API_Maker_Synthetic_Leather_and_Drug_Stocks\" title=\"What Are API Maker, Synthetic Leather and Drug Stocks?\">What Are API Maker, Synthetic Leather and Drug Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#API_Maker_Synthetic_Leather_and_Drug_Stocks_at_a_Glance\" title=\"API Maker, Synthetic Leather and Drug Stocks at a Glance\">API Maker, Synthetic Leather and Drug Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#Why_Do_API_Maker_Synthetic_Leather_and_Drug_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do API Maker, Synthetic Leather and Drug Stocks Have a Strong Roadmap in India?\">Why Do API Maker, Synthetic Leather and Drug Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#Why_Neuland_Laboratories_Features_Among_These_API_Maker_Synthetic_Leather_and_Drug_Stocks\" title=\"Why Neuland Laboratories Features Among These API Maker, Synthetic Leather and Drug Stocks\">Why Neuland Laboratories Features Among These API Maker, Synthetic Leather and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#Why_Mayur_Uniquoters_Features_Among_These_API_Maker_Synthetic_Leather_and_Drug_Stocks\" title=\"Why Mayur Uniquoters Features Among These API Maker, Synthetic Leather and Drug Stocks\">Why Mayur Uniquoters Features Among These API Maker, Synthetic Leather and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#Why_Torrent_Pharmaceuticals_Features_Among_These_API_Maker_Synthetic_Leather_and_Drug_Stocks\" title=\"Why Torrent Pharmaceuticals Features Among These API Maker, Synthetic Leather and Drug Stocks\">Why Torrent Pharmaceuticals Features Among These API Maker, Synthetic Leather and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#Neuland_Laboratories_vs_Mayur_Uniquoters_vs_Torrent_Pharmaceuticals_on_Key_Financials\" title=\"Neuland Laboratories vs Mayur Uniquoters vs Torrent Pharmaceuticals on Key Financials\">Neuland Laboratories vs Mayur Uniquoters vs Torrent Pharmaceuticals on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#Key_Risks_to_Check_Before_Investing_in_API_Maker_Synthetic_Leather_and_Drug_Stocks\" title=\"Key Risks to Check Before Investing in API Maker, Synthetic Leather and Drug Stocks\">Key Risks to Check Before Investing in API Maker, Synthetic Leather and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#Final_Thoughts_on_API_Maker_Synthetic_Leather_and_Drug_Stocks\" title=\"Final Thoughts on API Maker, Synthetic Leather and Drug Stocks\">Final Thoughts on API Maker, Synthetic Leather and Drug Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#What_are_API_maker_synthetic_leather_and_drug_stocks\" title=\"What are API maker, synthetic leather and drug stocks?\">What are API maker, synthetic leather and drug stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#Which_API_maker_synthetic_leather_and_drug_stocks_are_covered_in_this_list\" title=\"Which API maker, synthetic leather and drug stocks are covered in this list?\">Which API maker, synthetic leather and drug stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#Why_do_API_maker_synthetic_leather_and_drug_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do API maker, synthetic leather and drug stocks have a strong future roadmap in India?\">Why do API maker, synthetic leather and drug stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#How_has_Neuland_Laboratories_performed_financially\" title=\"How has Neuland Laboratories performed financially?\">How has Neuland Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#How_has_Mayur_Uniquoters_performed_financially\" title=\"How has Mayur Uniquoters performed financially?\">How has Mayur Uniquoters performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#How_has_Torrent_Pharmaceuticals_performed_financially\" title=\"How has Torrent Pharmaceuticals performed financially?\">How has Torrent Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#What_risks_should_investors_check_before_buying_API_maker_synthetic_leather_and_drug_stocks\" title=\"What risks should investors check before buying API maker, synthetic leather and drug stocks?\">What risks should investors check before buying API maker, synthetic leather and drug stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns-medicines-company-stocks-roadmap-skyline-list\/#Is_this_list_of_API_maker_synthetic_leather_and_drug_stocks_investment_advice\" title=\"Is this list of API maker, synthetic leather and drug stocks investment advice?\">Is this list of API maker, synthetic leather and drug stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_API_Maker_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>What Are API Maker, Synthetic Leather and Drug Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>API maker, synthetic leather and drug stocks are listed companies that make active ingredients for generic drugs, produce artificial leather and synthetic fabrics for footwear and autos, and sell cardiovascular and central nervous system medicines. Their earnings depend on export orders, prescriptions and input costs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"API_Maker_Synthetic_Leather_and_Drug_Stocks_at_a_Glance\"><\/span><strong>API Maker, Synthetic Leather and Drug Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/neulandlab\/neuland-laboratories-ltd-share-price-today\">Neuland Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19,424<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24,665<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">49.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.16<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/mayuruniq\/mayur-uniquoters-ltd-share-price-today\">Mayur Uniquoters<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">753.55<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,260<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/torntpharm\/torrent-pharmaceuticals-ltd-share-price-today\">Torrent Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,650<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">173,079<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">80.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.79<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Mayur Uniquoters trades at a P\/E below the industry P\/E, while Neuland Laboratories and Torrent Pharmaceuticals trade above it, which reflects the growth the market already expects. Readers comparing API maker, synthetic leather and drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in API maker, synthetic leather and drug stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_API_Maker_Synthetic_Leather_and_Drug_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do API Maker, Synthetic Leather and Drug Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>API maker, synthetic leather and drug stocks have a strong roadmap in India because steady global demand for generics, wider use of synthetic leather and steady chronic care demand keep widening the market for these export focused companies.<\/p>\n<ul>\n<li><strong>Generic supply.<\/strong> Regulated markets buy Indian ingredients.<\/li>\n<li><strong>Synthetic leather.<\/strong> Footwear and autos use synthetic fabrics.<\/li>\n<li><strong>Chronic care.<\/strong> Branded medicines bring repeat prescriptions.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Neuland_Laboratories_Features_Among_These_API_Maker_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>Why Neuland Laboratories Features Among These API Maker, Synthetic Leather and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the API maker, synthetic leather and drug stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.<\/p>\n<p>Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.<\/p>\n<p>The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P\/E of 49.5, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.<\/p>\n<p><strong>What to watch:<\/strong> Custom manufacturing revenue can move between quarters, so review the full-year trend.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Mayur_Uniquoters_Features_Among_These_API_Maker_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>Why Mayur Uniquoters Features Among These API Maker, Synthetic Leather and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the pharma and material exporters shares on this list, Mayur Uniquoters is a Rajasthan-based maker of artificial leather and synthetic fabrics used in footwear, automotive upholstery, furniture and other applications.<\/p>\n<p>The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P\/E of 15.7, below the industry P\/E of 37.9.<\/p>\n<p>Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.<\/p>\n<p><strong>What to watch:<\/strong> Check the volume trend in automotive and footwear customers and export sales.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Torrent_Pharmaceuticals_Features_Among_These_API_Maker_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>Why Torrent Pharmaceuticals Features Among These API Maker, Synthetic Leather and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.<\/p>\n<p>Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.<\/p>\n<p>In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.<\/p>\n<p><strong>What to watch:<\/strong> Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Neuland_Laboratories_vs_Mayur_Uniquoters_vs_Torrent_Pharmaceuticals_on_Key_Financials\"><\/span><strong>Neuland Laboratories vs Mayur Uniquoters vs Torrent Pharmaceuticals on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three API maker, synthetic leather and drug stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Neuland Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">953<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,053<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">364<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mayur Uniquoters<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">677<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,022<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">192<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Torrent Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,705<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13,886<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,138<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Torrent Pharmaceuticals has the largest FY26 revenue at Rs 13,886 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate. A useful habit with API maker, synthetic leather and drug stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_API_Maker_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>Key Risks to Check Before Investing in API Maker, Synthetic Leather and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these API maker, synthetic leather and drug stocks, the main points are: Long-term pharma and material exporters shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Currency moves.<\/strong> Export earnings move with the rupee.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter API maker, synthetic leather and drug stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_API_Maker_Synthetic_Leather_and_Drug_Stocks\"><\/span><strong>Final Thoughts on API Maker, Synthetic Leather and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>API maker, synthetic leather and drug stocks work best when investors track growth, valuation and return on equity side by side. Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals each have a clear plan to grow. Based on the 3 November 2026 close, Neuland Laboratories trades at Rs 19,424, Mayur Uniquoters at Rs 753.55 and Torrent Pharmaceuticals at Rs 4,650. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these API maker, synthetic leather and drug stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track API maker, synthetic leather and drug stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_API_maker_synthetic_leather_and_drug_stocks\"><\/span><strong>What are API maker, synthetic leather and drug stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> API maker, synthetic leather and drug stocks are listed companies that make active ingredients for generic drugs, produce artificial leather and synthetic fabrics for footwear and autos, and sell cardiovascular and central nervous system medicines. Their earnings depend on export orders, prescriptions and input costs. This list looks at three of them, Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_API_maker_synthetic_leather_and_drug_stocks_are_covered_in_this_list\"><\/span><strong>Which API maker, synthetic leather and drug stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals. Based on the 3 November 2026 close, Neuland Laboratories traded at Rs 19,424, Mayur Uniquoters at Rs 753.55 and Torrent Pharmaceuticals at Rs 4,650. Their return on equity ranges from 16.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.9% to 21.1%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_API_maker_synthetic_leather_and_drug_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do API maker, synthetic leather and drug stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> API maker, synthetic leather and drug stocks have a strong roadmap in India because steady global demand for generics, wider use of synthetic leather and steady chronic care demand keep widening the market for these export focused companies. The main drivers are as follows. Generic supply. Regulated markets buy Indian ingredients. Synthetic leather. Footwear and autos use synthetic fabrics. Chronic care. Branded medicines bring repeat prescriptions. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Neuland_Laboratories_performed_financially\"><\/span><strong>How has Neuland Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P\/E of 49.5, above the industry P\/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Mayur_Uniquoters_performed_financially\"><\/span><strong>How has Mayur Uniquoters performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P\/E of 15.7, below the industry P\/E of 37.9. Looking ahead, the company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Torrent_Pharmaceuticals_performed_financially\"><\/span><strong>How has Torrent Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_API_maker_synthetic_leather_and_drug_stocks\"><\/span><strong>What risks should investors check before buying API maker, synthetic leather and drug stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying API maker, synthetic leather and drug stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_API_maker_synthetic_leather_and_drug_stocks_investment_advice\"><\/span><strong>Is this list of API maker, synthetic leather and drug stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are API maker, synthetic leather and drug stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"API maker, synthetic leather and drug stocks are listed companies that make active ingredients for generic drugs, produce artificial leather and synthetic fabrics for footwear and autos, and sell cardiovascular and central nervous system medicines. Their earnings depend on export orders, prescriptions and input costs. This list looks at three of them, Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which API maker, synthetic leather and drug stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals. Based on the 3 November 2026 close, Neuland Laboratories traded at Rs 19,424, Mayur Uniquoters at Rs 753.55 and Torrent Pharmaceuticals at Rs 4,650. Their return on equity ranges from 16.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.9% to 21.1%.\"}},{\"@type\":\"Question\",\"name\":\"Why do API maker, synthetic leather and drug stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"API maker, synthetic leather and drug stocks have a strong roadmap in India because steady global demand for generics, wider use of synthetic leather and steady chronic care demand keep widening the market for these export focused companies. The main drivers are as follows. Generic supply. Regulated markets buy Indian ingredients. Synthetic leather. Footwear and autos use synthetic fabrics. Chronic care. Branded medicines bring repeat prescriptions. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Neuland Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P\/E of 49.5, above the industry P\/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.\"}},{\"@type\":\"Question\",\"name\":\"How has Mayur Uniquoters performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P\/E of 15.7, below the industry P\/E of 37.9. Looking ahead, the company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.\"}},{\"@type\":\"Question\",\"name\":\"How has Torrent Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying API maker, synthetic leather and drug stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying API maker, synthetic leather and drug stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of API maker, synthetic leather and drug stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>API Maker, Synthetic Leather and Drug Stocks with a strong future roadmap: Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals. Compare price, valuation, return on equity and revenue growth as of 3 November 2026.<\/p>\n","protected":false},"author":36,"featured_media":338488,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[19524,3803,19525,11015,8590,18759,18758,13963],"class_list":["post-338490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-api-maker","tag-best-stocks","tag-drug-and-material-exporters","tag-mayur-uniquoters","tag-neuland-laboratories","tag-pharma-and-material-exporters-shares","tag-synthetic-leather-and-drug-stocks","tag-torrent-pharmaceuticals"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["338488"],"rank_math_title":["API Maker, Synthetic Leather and Branded Drug Stocks"],"rank_math_description":["Compare 3 API maker, synthetic leather and drug stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 3 Nov 2026."],"rank_math_focus_keyword":["API maker, synthetic leather and drug stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-active-ingredients-maker-artificial-leather-maker-and-cardiovascular-and-cns.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/338490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=338490"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/338490\/revisions"}],"predecessor-version":[{"id":338491,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/338490\/revisions\/338491"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/338488"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=338490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=338490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=338490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}